Reading the Early Signals | AI Learning Guide

Take the three signals in turn and ask what each one would have to do to count as evidence. A trial readout counts because it is the point where someone outside the company can check the claim, and the interesting question is not whether one drug worked but whether the reasons for failure are changing. Regulatory guidance counts because agencies write rules for things that have become common enough to need them, so guidance tends to trail practice and its appearance tells you practice already moved. Adoption data counts because the last filter is the one inside the clinic, and a drug nobody prescribes has not changed anything. Now notice the trap: each of these is weak alone. One good trial can be luck, one guidance document can be routine paperwork. You are looking for a pattern that holds across several of them for several years, and that is a much higher bar than any single headline.

0:00 / 0:00

Auto-play

Where change would appear first

Trial readouts: published results of completed human studies, where a benefit claim becomes checkable and where a change in the pattern of failures would be informative
Regulatory guidance: published expectations for how a novel design method must be documented, which typically appears after a method has become common in practice
Adoption data: prescribing patterns, formulary decisions, and clinician commentary, which reveal whether approved drugs are actually reaching patients

Why single signals mislead

One successful trial can be a favorable draw from a noisy process. One guidance document can be routine. The informative thing is a sustained pattern across several signal types over several years, not any individual announcement.